Find Clinical Trials

Inclusion Criteria: * Male and female subjects aged between 18-65 years of age * Depressive patients: DSM-IV diagnosis of MDD following SCID I, HDRS29, MADRS and BDI-II * Satisfactory general health as determined by past medical history, physical examination, vital signs at screening * Vital signs measured after 3 minutes resting in the supine position must be within the following ranges: oral body temperature between 35.0-37.5 °C, systolic blood pressure 90-140 mmHg, diastolic blood pressure 50-90 mm Hg, pulse rate 40-100 bpm * Subjects must weigh 50-100 kg to participate in this study with a BMI within 19-26. * Sufficient visual and auditory performance for neuropsychological testing * Written informed consent will be obtained prior to the start of any study procedures. Therefore, willingness and competence to sign the informed consent form is needed. * Potential patients must be able to communicate well with the investigator and comply with the requirements of the study * Only participants who are legally authorized to give informed consent will be included in the present study. Exclusion Criteria: * Depressed patients: Presence of any severe / unstable neurological, somatic or psychiatric comorbidity * Healthy controls: Any psychiatric disease or any severe / unstable neurological or somatic disease * Presence of psychotic symptoms * Acute suicidality * Any contraindication for magnetic resonance or PET imaging * Presence of any metallic implant in the head * History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to one of the study drugs or multiple study drugs (known hypersensitivity to bupropion, escitalopram) * Other clinically significant abnormality on physical, neurological, or laboratory examination or on electrocardiogram (ECG) that, in the opinion of the investigator precludes the patient from the study * Ingestion of antidepressants or other psychotropic agents within the last 6 months Previous escitalopram- or bupropion intake * Antidepressive trials wit DBS, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or Ketamine * Current smoking, substance abuse including alcohol, drugs of abuse, or any medication in a manner which is indicative of substance-related disorders (e.g. substance dependency) according to DSM-IV * Failure to comply with the study protocol or follow the instructions of the investigators * Positive urine pregnancy test * Known pregnancy or lactation * MRI scan that shows evidence of stroke, infarct, or other space occupying lesion or structural abnormality * History of any other drug or alcohol abuse or misuse * Participation in any clinical investigation within 12 weeks prior to dosing * Evidence from an Allen test of incomplete communication between the radial and ulnar artery, in either hand * Significant radiation exposure (\>5 mSv) in the frame of participation in trials within the past 10 years

Inclusion Criteria: * Pediatric patients with end stage renal disease aged from 8 to 18 years on regular hemodialysis through functioning arteriovenous fistula and are fully oriented with time, persons and place at time of data collection. All participants either cases or controls suffer from anxiety, depression or both. Exclusion Criteria: * Children with temporary or permanent catheter for dialysis. * Children with mental illness, visual and auditory defects. * Children took any pharmacological pain reliever or antipsychotic drugs. * Non anxious or depressed Children.

Inclusion Criteria: * Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1) * Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study. Exclusion Criteria: * Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1). * Those who are expected to need insulin prescription during the study period.

Inclusion Criteria: * age (years) at least 18 years * no confounding health issue (i.e. no health conditions, other than asthma, that would put the participant at risk or affect data integrity as determined by the principal investigator) * baseline FEV1 ≥ 65% of predicted normal at Visit 1 * evidence of atopy to an allergen suitable for inhalation challenge following skin prick testing such as house dust mite, grass, cat or horse * fall in FEV1 of ≥ 20% at a dose of methacholine ≤ 600mcg (methacholine PD20) at Visit 1 * positive response to allergen inhalation challenge (fall in FEV1 of ≥ 15% after inhalation of allergen at a dilution 1:32 or more dillute. * absence of respiratory infection for at least 4 weeks prior to Visit 1 * absence of significant worsening of asthma that requires health care intervention or prolonged change in medication due to allergen exposure (or other trigger) for at least 4 weeks prior to Visit 1 * women of child-bearing potential shall not be pregnant or lactating * non-smoker (cigarettes, vaping); ex-smoker with \<10 pack year history allowed; cannabis use will be evaluated on a case-by-case basis * if on as needed budesonide/formoterol therapy, no reported use within 3 weeks prior to allergen challenge Exclusion Criteria: * Smoker \>10 pack year history

Inclusion Criteria: * Ability to provide written informed consent by subject or guardian * Individuals \>18 years of age * Diagnosis of an irAE clinically suspected to be IL-17 mediated * Intent-to-treat or prior treatment with systemic steroids for irAE management * Histology-proven primary advanced or metastatic solid organ malignancy treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll. * Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\< 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation. * Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test. * Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab. Exclusion Criteria: * Estimated creatinine clearance \< 40 mg/min * Active suicidal ideation or severe depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score \> 20 * History of prior suicide attempts * PHQ-9 score greater \>5 and \< 20 without an established mental health provider who verifies stability in their depression * Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV) * In the opinion of the investigator, the patient requires additional immunosuppressive treatment (other than corticosteroids and brodalumab) * Known hypersensitivity or contraindication to brodalumab, corticosteroids or any components of brodalumab * Prior treatment with brodalumab * Pregnancy, breastfeeding, or use of a nonreliable method of contraception * For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years postmenopausal, with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range). * Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method. * Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll * Chronic or current severe infection requiring IV therapy * Evidence of active hepatitis B, C, or tuberculosis. * History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated * History of or active Crohn's disease. * Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first investigational product dose * Any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject. * Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report * Other known clinically significant active medical conditions, such as: * Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D) * Aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal or greater than 3 times the upper limit of normal in patients with liver metastases measured on at least two separate occasions * Direct bilirubin greater than or equal to 1.5 mg/dL in patients with or without liver metastases * Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \<2000/mm3, absolute neutrophil count \<1500/ mm3, thrombocytopenia (platelet count) \<50,000/mm3, hemoglobin \< 8.0 g/dL * Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE * Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit * Previous diagnosis of an autoimmune disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration * Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation * Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab

Inclusion Criteria: * Have a BMI of * ≥30 kilograms per square meter (kg/m2) or * ≥27 kg/m2 and \<30 kg/m2, with at least one of the following weight-related comorbidities: * Hypertension * Dyslipidemia * Cardiovascular disease * Obstructive sleep apnea * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss) Exclusion Criteria: * Have a prior or planned surgical treatment for obesity * Have at least one laboratory value suggestive of diabetes during screening * Use of metformin, or any other glucose-lowering medications * Have Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma * Have poorly controlled hypertension * Have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes * Have ongoing or a history of bradyarrhythmias other than sinus bradycardia * Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure * Have a history of symptomatic gallbladder disease within the past 2 years * Have signs and symptoms of any liver disease * Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality * Have a history of acute or chronic pancreatitis * Have renal impairment, measured as estimated glomerular filtration rate \<30 mL/minute/1.73 m2 * Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

General Inclusion Criteria: 1. Willing to adhere to the prohibitions and restrictions specified in this protocol. 2. Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study and is willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol. 3. Patients aged ≥ 18 years at moment of signing informed consent form. 4. Life expectancy of \> 12 weeks. 5. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1. 6. BMI ≥ 18.0 and ≤ 35.0 kg/m2 and weight at least 50 kg and no more than 120 kg at screening. 7. Overtly healthy based on medical history, physical findings, vital signs, ECG at the time of screening, as judged by the Investigator. Note: one retest of vital functions and ECG is allowed within the screening window. 8. Adequate liver- and kidney function, defined by the following laboratory results obtained during screening visit: * AST, ALT, and alkaline phosphatase ≤ 2.5x the upper limit of normal (ULN) as determined by the UMCG laboratory reference values. * Serum bilirubin ≤ 2.0x ULN as determined by the UMCG laboratory reference values. Patients with known Gilbert disease who have serum bilirubin level ≤ 3x ULN may be enrolled. * INR or APTT ≤ 1.5x ULN as determined by the UMCG laboratory reference values. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. * eGFR (based on plasma-creatinine) = \>30 mL/min. * Serum albumin \>35 g/L. 9. No other clinically significant laboratory abnormalities as determined by the investigator. Note: one retest of lab tests is allowed within the screening window. 10. Female patients should be at least 1 year post-menopausal (amenorrhea \>12 months and/or follicle-stimulating hormone \>30 mIU/mL) at screening or surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation). 11. Male subjects who are sexually active with a female partner of childbearing potential must agree to the use of an effective method of birth control, and must not donate sperm, until 3 months after administration of 89Zr-DFO-N-Suc-scFv (F8 or C9). Medical inclusion Criteria: Colon Carcinoma: 1. Patients diagnosed with colon carcinoma stage I-IV, according to the 8th edition of the TNM-classification. 2. Histologically confirmed diagnosis of colon carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Rectal Carcinoma: 1. Patients diagnosed with rectal carcinoma stage I-IV, according to the 8th edition of the TNM-classification. 2. Histologically confirmed diagnosis of rectal carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Bone- and soft-tissue sarcoma 1. Patients diagnosed with a bone- or soft-tissue sarcoma stage I-IV, according to AJCC staging for Sarcoma. 2. Histologically confirmed diagnosis of sarcoma. 3. Neo-adjuvant treatment according to the standard of care. Breast carcinoma 1. Patients diagnosed with breast carcinoma stage I-IV, according to the 8th edition of the TNM-classification. 2. Histologically confirmed diagnosis of breast carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Lung Carcinoma: 1. Anticipated diagnosis of Non-Small Cell Lung Carcinoma (NSCLC) stage I-IV, according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)/CT or based on cytology. 2. Neo-adjuvant treatment according to the standard of care. Head and Neck Squamous Cell carcinoma (HNSCC): 1. Patients diagnosed with HNSCC of the oral cavity, oropharynx, nasal cavity, nasopharynx, hypopharynx and larynx. 2. Histologically confirmed diagnosis of HNSCC. 3. Neo-adjuvant treatment according to the standard of care. Oesophageal and gastric carcinoma: 1. Patients diagnosed with oesophagus carcinoma stage I-IV according to the 7th edition of the TNM-classification. 2. Patients diagnosed with gastric carcinoma stage I-IV according to the 7th edition of the TNM-classification. 3. Histologically confirmed diagnosis of oesophageal- or gastric carcinoma. 4. Neo-adjuvant treatment according to the standard of care. Pancreas carcinoma: 1. Anticipated diagnosis of pancreas carcinoma stage I-IV according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)/CT or based on cytology. 2. Histologically or cytologically confirmed diagnosis of pancreas carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Bladder carcinoma: 1. Patients diagnosed with invasive bladder carcinoma stage I-IV according to the 7th edition of the TNM-classification. 2. Histologically confirmed diagnosis of bladder carcinoma. 3. Neo-adjuvant treatment according to the standard of care. Glioblastoma: 1. Anticipated diagnosis of a high-grade glioma (glioblastoma, grade 4 according to the WHO classification) based on imaging modalities such as MRI and/or CT or a biopsy. 2. Karnofsky performance status of at least 70%. 3. Neo-adjuvant treatment according to the standard of care. General Exclusion Criteria: 1. Behavioral or cognitive impairment or psychiatric disease that, in the investigator's opinion, affects the patient's ability to understand and cooperate with the study protocol. 2. Insufficient venous access for the study procedures. 3. Close affiliation with the investigator, e.g. a close relative of the investigator, dependent person (e.g. employee or student), employee of the department of surgery or nuclear department of the UMCG,TRACER or affiliates. 4. Any finding in the medical examinations or medical history giving, in the opinion of the investigator, reasonable suspicion of a disease or condition that makes treatment with the investigational drug unadvisable, or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications. 5. Participation in an interventional clinical study within 30 days prior to tracer administration that involved treatment with any drug (excluding vitamins and minerals) or medical device. Medical Exclusion Criteria: 1. The existence of a second concomitant active malignancy or treatment for a second malignancy within 1 year prior to IMP-administration that is not a solid tumor indication included in the VARTUTRACE study, except for localized basal or squamous cell cancer that has been cured at least 90 days before screening. 2. Cardiac impairment with an estimated LVEF \<35 % Prolonged QTcF (\>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the investigator. 3. Any abnormalities in the vital signs of the patient, as judged by the investigator, as a result of which the patient cannot participate. Note: One retest of vital functions is allowed within the screening window. 4. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications. 5. Major surgical procedure other than for the included diagnosis within four weeks before IMP administration. Disease-related procedures, e.g. the placement of a port-a-cath, placement of a drain, ERCP, are allowed. 6. Current evidence or history of bacterial, viral or fungal infections within 7 days before 89Zr-DFON-Suc-scFv (F8 or C9) administration as judged by the Investigator. * T \> 38.0°C or lab confirmed viral/bacterial/fungal infection (PCR) or symptoms suggestive of an infection) * Received oral or IV antibiotics within \<7 days before administration. 7. Any planned major surgery within the duration of the study (until follow-up visit) that is not related

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Diagnosed with type 2 diabetes mellitus * A1c greater than or equal to 8.0 within two weeks of the time of enrollment * On insulin for at least one year +/- other antihyperglycemics * Ability and willingness to wear CGM for 14-day periods throughout the trial period * Ability and willingness to comply with provider-directed adjustments to medication regimen * Inability to afford CGM sensors A note on Vulnerable Populations: Many of FHCHC's patients are economically disadvantaged and of minority backgrounds; the clinic's patient base may be considered to constitute a vulnerable population. As such, recruitment and enrollment will be conducted within a vulnerable population. The nature of the study requires this, and the results are intended to directly benefit this population through the potential for improved glycemic control and quality of life. Exclusion Criteria: * Insulin naïve * Diabetic ketoacidosis (DKA) in previous 6 months * End-Stage Renal Disease (ESRD) * Contraindications to CGM use * Active insurance plan that would provide enough of a subsidy for participant to feasibly purchase CGM sensors * Pregnancy

Inclusion Criteria: * Female patients with newly diagnosed, local triple-negative breast cancer (stage I-III) ≥ 18 to 65 years of age scheduled for immunochemotherapy with pembrolizumab and anthracycline-based chemotherapy Exclusion Criteria: * Unstable cardiac condition (clinical suspicion of progress or unstable coronary artery disease, signs of acute heart failure, haemodynamically relevant arrhythmias) * Orthopaedic disability to exercise

Inclusion Criteria: 1. The patient voluntarily joined the study and signed an informed consent form; 2. ≥18 and ≤ 75 years old, both male and female; 3. Pathologically confirmed hepatocellular carcinoma, at least one measurable focus without local treatment (according to mRECIST or RECIST 1.1 requirements; 4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 5. BCLC-C stage accompanied by tumor thrombosis-associated portal hypertension; 6. Newly diagnosed patients who have not received local or systemic therapy in the past; 7. Expected survival period ≥ 3 months; 8. The functions of vital organs meet the following requirements (no blood components, cell growth factors and other corrective treatment drugs are allowed within 14 days before the first administration): the absolute count of neutrophils≥1.5×10\^9/L; Platelet ≥50×10\^9/L; Hemoglobin ≥60 g/L; Serum albumin ≥28 g/L; Thyroid-stimulating hormone (TSH)≤1×ULN (if abnormal, the levels of FT3 and FT4 should be examined at the same time, if the levels of FT3 and FT4 are normal, they can be included in the group); Bilirubin≤2×ULN (within 7 days before the first administration); ALT and AST ≤5×ULN (within 7 days before the first dose); Serum creatinine≤1.5×ULN; 9. Child-Pugh score ≤ 13 points; 10. Diagnosed with portal hypertension-related complications: Gastrointestinal bleeding; refractory or recurrent ascites; hepatic pleural effusion; portal vein tumor thrombus exceeds 50% of lumen area. 11. Non-surgical sterilization or female patients of childbearing age need to use a medically approved contraceptive method (such as an intrauterine device, contraceptive, or condom) during the study treatment period and within 3 months after the end of the study treatment period; Female patients of childbearing age who undergo surgical sterilization must be negative in serum or urine HCG within 72 hours before enrollment in the study; and must be non-lactating; for male patients whose partners are women of childbearing age, at the last time use effective methods for contraception within 3 months. Exclusion Criteria: 1. The patient has any active autoimmune disease or a history of autoimmune disease; 2. The patient is using immunosuppressive agents or systemic hormone therapy to achieve the purpose of immunosuppression (dose\>10mg/day prednisone or other curative hormones), and continues to use it within 2 weeks before enrollment; 3. Severe allergic reaction to any compositions of donafenib tablets or contrast media containing iodine ; 4. Central nervous system metastasis; 5. Patients who have received liver transplantation in the past; 6. Tumor thrombus beyond the portal vein range, such as hepatic vein, inferior vena cava, right atrium, splenic vein, superior mesenteric vein; 7. Suffer from high blood pressure and cannot be well controlled by anti-hypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); 8. Uncontrolled cardiac clinical symptoms or diseases, such as: NYHA level 2 or higher heart failure, unstable angina pectoris, myocardial infarction occurred within 1 year, clinically significant supraventricular or ventricular arrhythmia requires treatment or intervention , QTc\>450ms (male); QTc\>470ms (female); Abnormal coagulation function (INR\>2.0, PT\>16s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy, and allow the preventive use of low-dose aspirin and low molecular heparin; 9. Child-Pugh score \>13 points; 10. Arterial/venous thrombosis events that occurred within 6 months before randomization, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; 11. Known genetic or acquired bleeding and thrombotic tendency (such as hemophilia patients, coagulation dysfunction, thrombocytopenia, etc.); 12. Urine routine test showed urine protein ≥ ++ and confirmed 24-hour urine protein content\> 1.0 g; 13. The patient has active infection, fever of unknown origin within 7 days before medication ≥38.5℃, or baseline white blood cell count \>15×109/L; 14. Patients with congenital or acquired immune deficiencies (such as HIV-infected persons); 15. Moderate to severe pulmonary hypertension, pulmonary artery pressure was assessed by ultrasound \>40mmHg； 16. The patient suffered from other malignant tumors in the past 3 years or at the same time (except for cured skin basal cell carcinoma and cervical carcinoma in situ); 17. The patient has previously received other anti-PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1, or has previously received apatinib therapy; 18. According to the judgment of the investigator, the patient has other factors that may affect the results of the study or cause the study to be terminated halfway, such as alcoholism, drug abuse, other serious diseases (including mental illness) that require combined treatment, and other abnormalities which may affect the efficacy and/or safety of patients.

Inclusion Criteria: * aged 18-45 years * at 20-24 weeks of gestation * at risk of depression but not experiencing severe depressive symptoms at recruitment, as indicated by an Edinburgh Postnatal Depression Scale (EPDS) score of between 5 and 12 * own a smartphone * are able to independently engage with the program Exclusion Criteria: * have serious medical conditions or pregnancy complications that may affect their psychological condition, as determined by their medical doctor * have a prior diagnosis of any mental disorders * are currently or were recently (within the past six months) receiving any kinds of psychological services or treatments * have a history of self-harm or suicide * have any suicidal thoughts in the past 12 months * experienced fetal deaths in the past 18 months

Inclusion Criteria: * Persons 18 years of age or older who present as patients in the Robert Wood Johnson University Hospital Emergency Department with or without a preexisting Type 2 Diabetes Mellitus diagnosis with a blood glucose of ≥200 mg/dL. Participants must speak English to participate in the study. Exclusion Criteria: * Age less than 18 years and blood glucose \&lt;200 mg/dL.

Inclusion Criteria: * moderate depression per PHQ9 symptom ratings Exclusion Criteria: * active substance abuse/dependence * psychotic disorders * bipolar disorder * displaying acutely suicidal behaviors

Inclusion Criteria: * Resident doctors undergoing post-graduation training in Hospital. * Resident in hospitals in Upper Egypt Exclusion Criteria: * Resident doctors who were already under treatment for any psychiatric disorder and chronic medical illnesses.

Inclusion Criteria: * Histologically confirmed ductal carcinoma in situ (DCIS) and invasive breast cancer. * Age ≥ 45 * cT1/cN0, tumor size ≤ 2.5cm * ECOG 0\~2 -ER+, HER2- Exclusion Criteria: * cN+ * Tumor located too close to the skin or chest wall (within 5 mm) * With previous treatment history for breast cancer * Neoadjuvant chemotherapy * Multicentric disease * Diffuse microcalcification * BRCA mutation * Paget's disease * In cases where tumor delineation is not achievable on CT/MRI images

Inclusion Criteria: Potential subjects are required to meet all of the following criteria for enrollment into the study. 1. At least 18 years old, inclusive. 2. Presence of a DFU, Wagner Grade 1, extending through the dermis provided it is below the medial aspect of the malleolus. 3. The index ulcer (ulcer to be evaluated in the study) will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer. 4. Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study. 5. Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1. 6. Within 3 months of SV1, adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \> 0.6 is acceptable. 7. The target ulcer has been offloaded for at least 14 days, prior to TV1. 8. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests. 9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits. 10. Subjects must have read and signed the IRB approved ICF before screening procedures are performed. Exclusion Criteria: Potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent treatment. 1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes 2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer 3. Index ulcer is infected 4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study 5. Subjects on any investigational drug(s), Investigational products, or therapeutic device(s) within 30 days preceding SV1 6. History of radiation at the ulcer site (regardless of time since last radiation treatment) 7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies 8. Subjects with a previous diagnosis of HIV or Hepatitis C 9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment 10. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision) 11. Subject is pregnant or breast-feeding 12. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 within last 90 days 13. Subjects with end stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of enrollment 14. Presence of acute Charcot Neuroarthropathy to the affected limb 15. Index ulcer that has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit

Inclusion Criteria: * Group HDC: * Patient followed at the CCMR (centres de compétence maladies rares) HDC of the Strasbourg University Hospital * Aged between 3 and 17 years old inclusive * Indifferent Sex * Subject affiliated to a social protection health insurance scheme or beneficiary of such a scheme * Subject able to understand the objectives and risks of the research and to provide dated and signed informed consent * Subject who has been informed of the results of the preliminary medical examination Control group: * Subject followed in pediatric surgery * Aged between 3 and 17 years old inclusive * Indifferent Sex * Subject affiliated to a social protection health insurance scheme or beneficiary of such a scheme * Subject able to understand the objectives and risks of the research and to provide dated and signed informed consent * Subject who has been informed of the results of the preliminary medical examination Exclusion Criteria: * Group HDC: * Refusal * Language barrier * Diaphragmatic surgery within the last 3 months * Patient with a viral picture in progress at the time of examination (assessment by the investigator) * Patient treated with muscle relaxant * Inability to give the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.) * Subject under safeguard of justice * Subject under guardianship or curatorship * Pregnant or breastfeeding woman Control group: * Patient without thoracic pathology * Refusal * Language barrier * Diaphragmatic pathology * Any myopathy * History of surgery of the upper digestive tract (esophagus and/or gastric and/or duodenal) * Patient on muscle relaxant * Patient with a viral picture in progress at the time of examination (assessment by the investigator) * Patient treated with muscle relaxant * Inability to give the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.) * Subject under safeguard of justice * Subject under guardianship or curatorship * Pregnant or breastfeeding woman

Inclusion Criteria: * HER2 + metastatic breast cancer * Pre / post menopausal * Previously treated with anti-HER2 therapy * Continuing CR or PR for more than 2 year Exclusion Criteria: * Patients who were deemed inappropriate as research subjects based on the physician's judgment, such as those possibly receiving inappropriate treatment.

Inclusion Criteria(Breast malignant nodule group) 1. Korean nationality 2. Voluntary written consent to participate in this clinical performance trial study 3. Confirmed breast cancer through imaging/pathologic diagnostic tests 4. Those who have been diagnosed with breast cancer at a stage prior to treatment and surgery, and who agree to participate in this study and are able to provide blood samples. 5. Those whose lesions have been confirmed by conventional examination (breast ultrasound or mammography) and who fall into BI-RADS categories 4,5,6 and have undergone biopsy or are scheduled to undergo biopsy within 2 weeks. 6. Those who meet the following demographic conditions A. Adult female, 40 years of age or older 7. Those who can provide the following clinical information A. Age and biological sex B. Whether or not they have dense breasts C. Occupational information D. Pathological tumor size, Clinical tumor size, Pathological TNM staging, Clinical TNM staging, tumor location, breast cancer histology findings (breast cancer subtype) E. Family history and past history of cancer F. Breast-related diseases G. Chronic disease history Inclusion Criteria(Breast benign nodule group) 1. Korean nationality 2. Voluntary written consent to participate in this clinical performance trial study 3. Diagnosed with breast nodules through imaging/pathologic diagnostic tests 4. Those who have been diagnosed with breast nodules and have agreed to participate in this study and are able to provide blood samples at a stage prior to treatment and surgery. 5. Those whose lesions have been confirmed by conventional examination (breast ultrasound or mammography) and fall into BI-RADS categories 4,5,6 and have undergone biopsy or are scheduled for biopsy within 2 weeks 6. Those who meet the following demographic conditions A. Adult female, 40 years of age or older 7. Those who can provide the following clinical information A. Age and biological sex B. Whether or not they have dense breasts C. Occupational information D. Diagnosis, nodule size, and number of nodules E. Family history and past history of cancer F. Breast-related diseases G. Chronic disease history Exclusion Criteria: 1. Those who have been diagnosed with cancer (malignant tumor) of any type within 5 years of the date of consent and have undergone appropriate chemotherapy/radiation treatment or surgery. 2. Those who are confirmed to have developed breast cancer due to metastasis from malignant tumors other than breast cancer 3. Pregnant women 4. Participation in a drug-related clinical trial within 3 months of the date of the informed consent form

Inclusion Criteria: * Middle school students studying in school and their parents * Capable of hearing, speaking, reading, and writing Exclusion Criteria: * High suicidal risks * Severe mental disorders